Monopar Therapeutics Inc.
MNPR
Price:
$5.71
Market Cap:
$20.10M
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimm...[Read more]
Industry
Biotechnology
IPO Date
2019-12-19
Stock Exchange
NASDAQ
Ticker
MNPR
PE Ratio
[-2.43]
ROE
[-110.60%]
Current Ratio
[6.59]
Dividend Yield
[0%]
Enterprise Value
[13.98M]
Dividend History
The ROE as of October 2024 (TTM) for Monopar Therapeutics Inc. (MNPR) is -110.60%
According to Monopar Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -110.60%. This represents a change of 294.53% compared to the average of -28.03% of the last 4 quarters.
Monopar Therapeutics Inc. (MNPR) Historical ROE (quarterly & annually)
How has MNPR ROE performed in the past?
The mean historical ROE of Monopar Therapeutics Inc. over the last ten years is -73.36%. The current -110.60% ROE has changed 50.76% with respect to the historical average. Over the past ten years (40 quarters), MNPR's ROE was at its highest in in the June 2016 quarter at 0%. The ROE was at its lowest in in the September 2017 quarter at -145.00%.
Average
-73.36%
Median
-46.66%
Minimum
-172.10%
Maximum
-24.96%
Monopar Therapeutics Inc. (MNPR) ROE by Quarter and Year
Discovering the peaks and valleys of Monopar Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 310.95%
Maximum Annual ROE = -24.96%
Minimum Annual Increase = -72.89%
Minimum Annual ROE = -172.10%
| Year | ROE | Change |
|---|---|---|
| 2023 | -150.37% | 44.57% |
| 2022 | -104.01% | 116.99% |
| 2021 | -47.93% | 20.88% |
| 2020 | -39.66% | 21.37% |
| 2019 | -32.67% | -29.97% |
| 2018 | -46.66% | -72.89% |
| 2017 | -172.10% | 310.95% |
| 2016 | -41.88% | 67.81% |
Monopar Therapeutics Inc. (MNPR) Average ROE
How has MNPR ROE performed in the past?
The current ROE of Monopar Therapeutics Inc. (MNPR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-100.77%
5-year avg
-74.93%
10-year avg
-73.36%
Monopar Therapeutics Inc. (MNPR) ROE vs. Peers
How is MNPR’s ROE compared to its peers?
Monopar Therapeutics Inc.’s ROE is greater than Anebulo Pharmaceuticals, Inc. (-138.92%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Candel Therapeutics, Inc. (-629.29%), greater than Acurx Pharmaceuticals, Inc. (-371.20%), greater than Enochian Biosciences, Inc. (-47.54%), greater than scPharmaceuticals Inc. (-201.84%), greater than DiaMedica Therapeutics Inc. (-38.56%), less than Scopus BioPharma Inc. (911.69%), greater than Pasithea Therapeutics Corp. (-74.63%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Adagene Inc. (-50.10%), greater than Rezolute, Inc. (-70.73%),
| Company | ROE | Market cap |
|---|---|---|
| -138.92% | $47.46M | |
| -47.31% | $243.75M | |
| -21.96% | $82.43M | |
| -33.08% | $165.31M | |
| -42.61% | $690.21M | |
| -629.29% | $188.34M | |
| -371.20% | $32.82M | |
| -47.54% | $45.38M | |
| -201.84% | $219.63M | |
| -38.56% | $183.39M | |
| 911.69% | $16.83K | |
| -74.63% | $4.17M | |
| -54.72% | $30.74M | |
| -36.89% | $1.15B | |
| -62.74% | $289.07M | |
| -83.65% | $66.97M | |
| -50.10% | $106.69M | |
| -70.73% | $265.10M |
Build a custom stock screener for Monopar Therapeutics Inc. (MNPR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monopar Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Monopar Therapeutics Inc. (MNPR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Monopar Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Monopar Therapeutics Inc.'s ROE?
How is the ROE calculated for Monopar Therapeutics Inc. (MNPR)?
What is the highest ROE for Monopar Therapeutics Inc. (MNPR)?
What is the 3-year average ROE for Monopar Therapeutics Inc. (MNPR)?
What is the 5-year average ROE for Monopar Therapeutics Inc. (MNPR)?
How does the current ROE for Monopar Therapeutics Inc. (MNPR) compare to its historical average?